BioSpace News Archive

Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board member with experience in pharma, biotech, and venture capital, has been elected as a member of the Delcath Board of Directors effective February 14, 2020.

Thesecondopinion, a nonprofit offering free multidisciplinary, comprehensive second opinions to adults diagnosed with new or recurrent cancers, announced today it is hosting Dr. Robert M. Sapolsky—one of the world’s leading neuroscientists and acclaimed best-selling author, stress expert and biologist—at its 6th Annual Benefit event.

Kowa Research Institute, Inc., announced the achievement of its goal to randomize 10,000 subjects into its international, multi-center Phase 3 cardiovascular outcomes trial titled “Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes” (PROMINENT).

RedDress, a privately held, Israel and U.S. based company, today announced the U.S. launch of ActiGraft, the first wound treatment that transforms – in real time – a patient’s blood into an autologous whole blood clot tissue

CCRM Fertility, a global pioneer in fertility science, research and advancement, announced the expansion of its Dallas-Fort Worth network with a new office located at Medical City Dallas in the North Dallas area at 7777 Forest Lane, Dallas, TX.

Myomo, Inc. announced that it has signed an agreement with HOMELINK which will enable Myomo to process out-of-network claims for its MyoPro powered orthosis with the 1,200 payers in HOMELINK’s network.

Feb. 19, 2020 13:00 UTC Partnership augments caresyntax’s digital ecosystem in surgery, accelerates solution delivery and increases integration capacity. BOSTON--( BUSINESS WIRE )-- caresyntax, a pioneer in surgical automation, quality analytics and AI software and technologies, today announced the launch of a new partnership with Diversified, an industry leading technology solutions integrator. The partnership will enable caresyntax to accelerate the development and deploy

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 27, 2020 prior to the open of the market.

Endo International plc announced that Blaise Coleman, who has served as the Company’s Executive Vice President and Chief Financial Officer since 2016, will succeed Paul Campanelli as President and Chief Executive Officer and will become a member of the Board of Directors effective March 6, 2020.

ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, reported its financial results for the fourth quarter and full year ended December 31, 2019.